Global Vaccine Market, People Vaccinated, Vaccines Administered, Immunization, By Disease, By End User & Companies

  • ID: 4577477
  • Report
  • Region: Global
  • 355 Pages
  • Renub Research
1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from the emerging countries is expected to boost the global vaccine businesses in the near future.

The vaccine is a safe and effective biological preparation, which improves the immunity against a particular disease. Technological advancement, rising demand for low cost products and widespread routine immunization programmes in several countries around the world will certainly expect to stimulate the growth of the vaccine market in the following years. Also, rising demand for combinations vaccines as it provides immunization against several diseases in a single shot is further expected to boost the vaccine business growth.

The report titled “Global Vaccine Market, People Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, Combination Vaccine, Travel & Miscellaneous Vaccine], By End User [Infants (Pediatric), & Adult], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years

The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, Combination Vaccine, Travel & Miscellaneous Vaccine. Influenza, Pneumococcal, Meningococcal, Hepatitis and Combination Vaccines together hold the significant market share and is expected to continue so.

By End User – Infants (Pediatric) Segment leads the Global Vaccine Market

The report studies the market by end user as Infants (Pediatric) and Adults. It is found that the market for Infants (Pediatric) segment is huge because as most of the countries now have included a series of vaccines to their National Immunization Programme as the per WHO recommendations. For the year 2017; Combos (Combination Vaccines) has the maximum immunization share among all pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) studied in the report as they protect against more ailments in single shot, people preferring to get combination vaccine instead of a specific vaccine.

Company Analysis

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Our analysis found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administration in future due to the rising concern against the life-threatening vaccine-preventable diseases around the world.

By Disease:

  • Influenza
  • Cervical Cancer
  • Zoster (Shingles)
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Haemophilus influenzae type B
  • Polio
  • Rotavirus
  • Varicella
  • Combination Vaccine
  • Travel & Miscellaneous Vaccine

By End User:

  • Infants (Pediatric)
  • Adults

Key Companies Covered in the Report:

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer

Global Vaccine Market has been extensively studied from 3 major points, and further sub-divided into 2 more points:   

  • World Vaccines (Disease wise) Market & Forecast
    •  Adult Vaccines Market
    •  Pediatrics Vaccines Market
  • Number of Vaccinated People (Disease wise) & Forecast
    •  Number of Vaccinated Adult
    •  Number of Vaccinated Infants (Pediatric)
  • Doses of Vaccines Administered (Disease wise) & Forecast
    •  Doses of vaccines administered in Adults
    •  Doses of vaccines administered in Infants (Pediatric)
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

1. Research Findings

2. Global – Vaccines Market and Forecast
2.1 Adult Vaccines Market
2.2 Pediatric (Infant) Vaccines Market

3. Global – Adult Vaccine vs. Pediatric Vaccine Market Share

4. Global – Vaccines Market Share and Forecast
4.1 Adult Vaccines Market Share
4.2 Pediatric (Infant) Vaccines Market Share

5. Global – Vaccinated People
5.1 Adult Immunized and Forecast
5.2 Vaccinated Infant (Pediatric)

6. Global – Vaccinated People Share
6.1 Vaccinated Adult Share
6.2 Vaccinated Infant (Pediatric) Share

7. Global – Doses of Vaccines Administered and Forecast
7.1 Doses of Adult Vaccines Administered
7.2 Doses of Infant (Pediatric) Vaccines Administered

8. Global – Doses of Vaccines Administered Share
8.1 Doses of Vaccines Administered to Adult Share
8.2 Doses of Vaccines Administered to Infant (Pediatric) Share

9. Global – Vaccine Companies Market Share and Forecast

10. Disease wise – Vaccines Market and Forecast
10.1 Influenza – Total Vaccines Market
10.1.1 Influenza – Adult Vaccines Market
10.1.2 Influenza – Pediatric (Infant) Vaccines Market
10.2 Cervical Cancer (HPV) – Vaccines Market
10.3 Zoster (Shingles) – Vaccines Market
10.4 MMR (Measles, Mumps, and Rubella Vaccine) – Total Vaccines Market
10.4.1 MMR – Adult Vaccines Market
10.4.2 MMR – Pediatric (Infant) Vaccines Market
10.5 Pneumococcal – Total Vaccines Market
10.5.1 Pneumococcal – Adult Vaccines Market
10.5.2 Pneumococcal – Pediatric (Infant) Vaccines Market
10.6 Meningococcal – Total Vaccines Market
10.6.1 Meningococcal – Adult Vaccines Market
10.6.2 Meningococcal – Pediatric (Infant) Vaccines Market
10.7 Hepatitis – Total Vaccines Market
10.7.1 Hepatitis – Adult Vaccines Market
10.7.2 Hepatitis – Pediatric (Infant) Vaccines Market
10.8 TdaP and DTaP – Total Vaccines Market
10.8.1 TdaP – Adult Vaccines Market
10.8.2 DTaP – Pediatric (Infant) Vaccines Market
10.9 Travel and Miscellaneous – Vaccines Market
10.10 Haemophilus Influenzae Type B (HIB) – Vaccines Market
10.11 Combos (Combination) – Vaccines Market
10.12 Polio – Vaccines Market
10.13 Rotavirus – Vaccines Market
10.14 Varicella – Vaccines Market
10.14.1 Varicella – Adult Vaccines Market
10.14.2 Varicella – Pediatric (Infant) Vaccines Market

11. Disease wise – Numbers of Vaccinated People & Forecast
11.1 Influenza – Total Number of Vaccinated People
11.1.1 Influenza – Number of Vaccinated Adults
11.1.2 Influenza – Number of Vaccinated Infants
11.2 Cervical Cancer (HPV) – Number of Vaccinated People
11.3 Zoster (Shingles) – Number of Vaccinated People
11.4 MMR – Total Number of Vaccinated People
11.4.1 MMR – Number of Vaccinated Adults
11.4.2 MMR – Number of Vaccinated Infants (Pediatric)
11.5 Pneumococcal – Total Number of Vaccinated People
11.5.1 Pneumococcal – Number of Vaccinated Adults
11.5.2 Pneumococcal – Number of Vaccinated Infants
11.6 Meningococcal – Total Number of Vaccinated People
11.6.1 Meningococcal – Number of Vaccinated Adults
11.6.2 Meningococcal – Number of Vaccinated Infants
11.7 Hepatitis – Total Number of Vaccinated People
11.7.1 Hepatitis – Number of Vaccinated Adults
11.7.2 Hepatitis – Number of Vaccinated Infants
11.8 TdaP and DTaP – Total Number of Vaccinated People
11.8.1 TdaP – Number of Vaccinated Adults
11.8.2 DTaP – Number of Vaccinated Infants
11.9 Hib (Haemophilus Influenzae Type B) – Number of Vaaccinated Infants
11.10 Combos (Combination Vaccines) – Number of Vaccinated Infants
11.11 Polio – Number of Infants Immunized and Forecast
11.12 Rotavirus – Number of Vaccinated Infants
11.13 Varicella – Total Number of Vaccinated People
11.13.1 Varicella – Number of Vaccinated Adults
11.13.2 Varicella – Number of Vaccinated Infants

12. Disease wise – Doses of Vaccines Administered and Forecast
12.1 Influenza – Doses of Vaccines Administered
12.1.1 Influenza – Doses of Adult Vaccines Administered
12.1.2 Influenza – Doses of Infant Vaccines Administered
12.2 Cervical Cancer (HPV) – Doses of Vaccines Administered
12.3 Zoster (Shingles) – Doses of Vaccines Administered
12.4 MMR – Doses of Vaccines Administered
12.4.1 MMR – Doses of Adult Vaccines Administered
12.4.2 MMR – Doses of Infant Vaccines Administered
12.5 Pneumococcal – Doses of Vaccines Administered
12.5.1 Pneumococcal – Doses of Adult Vaccines Administered
12.5.2 Pneumococcal – Doses of Infant Vaccines Administered and Forecast
12.6 Meningococcal – Doses of Vaccines Administered
12.6.1 Meningococcal – Doses of Adult Vaccines Administered
12.6.2 Meningococcal – Doses of Infant Vaccines Administered
12.7 Hepatitis – Doses of Vaccines Administered
12.7.1 Hepatitis – Doses of Adult Vaccines Administered
12.7.2 Hepatitis – Doses of Infant Vaccines Administered
12.8 TdaP and DTaP – Doses of Vaccines Administered
12.8.1 TdaP – Doses of Adult Vaccines Administered and Forecast
12.8.2 DTaP – Doses of Infant Vaccines Administered
12.9 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
12.10 Polio – Doses of Infant Vaccines Administered
12.11 Rotavirus – Doses of Infant Vaccines Administered and Forecast
12.12 Varicella – Doses of Vaccines Administered
12.12.1 Varicella – Doses of Adult Vaccines Administered
12.12.2 Varicella – Doses of Infant Vaccines Administered

13. Disease wise - Immunization Profile
13.1 Immunization Coverage (%) in Infants
13.2 Global Immunization Profile
13.3 Regional Immunization Profile
13.3.1 Measles – Number of Reported Cases
13.3.2 Mumps – Number of Reported Cases
13.3.3 Rubella – Number of Reported Cases
13.3.4 Rubella (CRS) – Number of Reported Cases
13.3.5 Diphtheria – Number of Reported Cases
13.3.6 Tetanus (Neonatal) – Number of Reported Cases
13.3.7 Tetanus (Total) – Number of Reported Cases
13.3.8 Pertussis – Number of Reported Cases
13.3.9 Polio – Number of Reported Cases
13.3.10 Yellow Fever – Number of Reported Cases
13.3.11 Japanese encephalitis – Number of Reported Cases

14. Vaccines Key Players Sales and Forecast
14.1 GlaxoSmithKline, plc.’s Vaccines Sales
14.2 Merck & Co. Vaccines Sales
14.3 Sanofi Pasteur’s Vaccines Sales
14.4 Pfizer, Inc.’s Vaccines Sales
14.5 Global – Other Companies Vaccines Sales

15. Vaccines – Products and Pipeline
15.1 GSK Vaccine Product Pipeline
15.2 Merck Vaccine Product Pipeline
15.3 Sanofi Vaccine Product Pipeline
15.4 Pfizer Vaccine Product Pipeline

16. Top Mergers and Acquisitions in the Vaccine Industry

17. Vaccines and Regulator’s Interventions
17.1 Making and Meeting Standards of Quality and Safety
17.2 Vaccine Funding

18. Vaccine Market Drivers
18.1 Inclusion in National Immunization Schedule
18.2 Growing Immunization Coverage for HPV Vaccines
18.3 Increase in Prevalence of Infectious Diseases
18.4 Global Immunization Vision and Strategy (GIVS)
18.5 GAVI Model Fuelling Vaccine Manufacturers
18.5.1 The Partnership Model
18.5.2 The Business Model
18.6 Increasing Vaccine Availability in United States
18.7 The Vaccine Safety Data link Project
18.8 The Vaccine Injury Compensation Program
18.9 Transforming of Vaccine Technologies
18.10 Global Vaccine Action Plan by WHO (2011 - 2020)
18.11 Continuous Focus on Effective Communication Strategies

19. Vaccines Market Challenges
19.1 Hurdles to Optimal use of Licensed Vaccines
19.1.1 Technical Obstacles
19.1.2 Economic Obstacles
19.1.3 Cultural Obstacles
19.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
19.2.1 Legal Obstacles
19.2.2 General Technical Barriers
19.2.3 Economic Barriers
19.2.4 Regulatory Barriers
19.3 Shortening the Timeline for Vaccine Development
19.4 Refusal/Resistance to Vaccination
19.4.1 Vaccine Adverse Event Reporting System
19.5 Vaccine Shortages and Delays
19.6 Obstacles in Vaccine Research & Development
19.7 Barriers to New Entrants in the Vaccines Market

List of Figures
Figure 2 1: Global – Vaccines Market (Billion US$), 2011 - 2017
Figure 2 2: Global – Forecast for Vaccines Market (Billion US$), 2018 – 2024
Figure 2 3: Global – Adult Vaccines Market (Billion US$), 2011 – 2017
Figure 2 4: Global – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 2 5: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2017
Figure 2 6: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 – 2024
Figure 3 1: Global – Adult Vs. Pediatric Vaccine Market Share, 2011- 2017
Figure 3 2: Global – Forecast for Adult Vs. Pediatric Vaccine Market Share, 2018 - 2024
Figure 4 1: Global – Vaccines Market Share (Percent), 2011 - 2017
Figure 4 2: Global – Forecast for Vaccines Market Share (Percent), 2018 - 2024
Figure 4 3: Global – Adult Vaccines Market Share (Percent), 2011 - 2017
Figure 4 4: Global – Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
Figure 4 5: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2017
Figure 4 6: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2024
Figure 5 1: Global – Vaccinated People (Million), 2011 - 2017
Figure 5 2: Global – Forecast for Vaccinated People (Million), 2018 - 2024
Figure 5 3: Global – Number of Vaccinated Adult (Million), 2011 – 2017
Figure 5 4: Global – Forecast for Number of Vaccinated Adult (Million), 2018 – 2024
Figure 5 5: Global – Number of Vaccinated Infant (Pediatric) (Million), 2011 - 2017
Figure 5 6: Global – Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018 – 2024
Figure 6 1: Global – Vaccinated Adult Share (Percent), 2011 - 2017
Figure 6 2: Global – Forecast for Vaccinated Adult Share (Percent), 2018 – 2024
Figure 6 3: Global – Vaccinated Infant (Pediatric) Share (Percent), 2011 – 2017
Figure 6 4: Global – Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018 – 2024
Figure 7 1: Global – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 7 2: Global – Forecast for Doses of Vaccines Administered (Million), 2018 – 2024
Figure 7 3: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 7 4: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 7 5: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2017
Figure 7 6: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018 - 2024
Figure 8 1: Global – Doses of Vaccines Administered Share (Percent), 2011 - 2017
Figure 8 2: Global – Forecast for Doses of Vaccines Administered Share (Percent), 2018 - 2024
Figure 8 3: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
Figure 8 4: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
Figure 8 5: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2017
Figure 8 6: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018 - 2024
Figure 9 1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 9 2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 10 1: Influenza – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10 2: Influenza – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10 3: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10 4: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 10 5: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10 6: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10 7: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2017
Figure 10 8: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10 9: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2017
Figure 10 10: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10 11: MMR – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10 12: MMR – Forecast for Total Vaccines Market (Billion US$), 2018 – 2024
Figure 10 13: MMR – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 10 14: MMR – Forecast for Adult Vaccines Market (Million US$), 2018 – 2024
Figure 10 15: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2017
Figure 10 16: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10 17: Pneumococcal – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10 18: Pneumococcal – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10 19: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10 20: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 10 21: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2017
Figure 10 22: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018 - 2024
Figure 10 23: Areas with frequent epidemics of meningococcal meningitis
Figure 10 24: Meningococcal – Total Vaccines Market (Million US$), 2011 – 2017
Figure 10 25: Meningococcal – Forecast for Total Vaccines Market (Million US$), 2018 – 2024
Figure 10 26: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 10 27: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10 28: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10 29: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10 30: Hepatitis – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10 31: Hepatitis – Forecast for Total Vaccines Market (Billion US$), 2018 - 2024
Figure 10 32: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 10 33: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 10 34: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10 35: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10 36: TdaP and DTaP – Total Vaccines Market (Million US$), 2011 - 2017
Figure 10 37: TdaP and DTaP – Forecast for Total Vaccines Market (Million US$), 2018 - 2024
Figure 10 38: TdaP – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 10 39: TdaP – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10 40: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10 41: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 10 42: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2017
Figure 10 43: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10 44: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2017
Figure 10 45: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10 46: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2017
Figure 10 47: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 10 48: Polio – Vaccines Market (Million US$), 2011 - 2017
Figure 10 49: Polio – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10 50: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
Figure 10 51: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
Figure 10 52: Rotavirus – Vaccines Market (Million US$), 2011 - 2017
Figure 10 53: Rotavirus – Forecast for Vaccines Market (Million US$), 2018 - 2024
Figure 10 54: Varicella – Total Vaccines Market (Billion US$), 2011 - 2017
Figure 10 55: Varicella – Forecast for Total Vaccines Market (Billion US$), 2018 – 2024
Figure 10 38: Varicella – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 10 39: Varicella – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 10 40: Varicella – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2017
Figure 10 41: Varicella – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2024
Figure 11 1: Influenza – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 2: Influenza – Forecast for Total Number of Vaccinated People (Million), 2018 – 2024
Figure 11 3: Influenza – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 4: Influenza – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 5: Influenza – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 6: Influenza – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 7: Cervical Cancer – Number of Vaccinated People (Million), 2011 - 2017
Figure 11 8: Cervical Cancer – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 11 9: Zoster (Shingles) – Number of Vaccinated People (Million), 2011 - 2017
Figure 11 10: Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 11 11: MMR – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 12: MMR – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11 13: MMR – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 14: MMR – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 15: MMR – Number of Vaccinated Infants (Pediatric) (Million), 2011 - 2017
Figure 11 16: MMR – Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2024
Figure 11 17: Pneumococcal – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 18: Pneumococcal – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11 19: Pneumococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 20: Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 21: Pneumococcal – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 22: Pneumococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 23: Meningococcal – Total Number of People Immunized (Million), 2011 – 2017
Figure 11 24: Meningococcal – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11 25: Meningococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 26: Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 27: Meningococcal – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 28: Meningococcal – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 29: Hepatitis – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 30: Hepatitis – Forecast for Total Number of vaccinated People (Million), 2018 - 2024
Figure 11 31: Hepatitis – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 32: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2018 - 2024
Figure 11 33: Hepatitis – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 34: Hepatitis – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 35: TdaP and DTaP – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 36: TdaP and DTaP – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11 37: TdaP – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 38: TdaP – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 39: DTaP – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 40: DTaP – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 41: Hib (Haemophilus Influenzae Type B) – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 42: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 43: Combos (Combination Vaccines) – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 44: Combos (Combination Vaccines) – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 45: Polio – Number of Infants Immunized (Million), 2011 - 2017
Figure 11 46: Polio – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 11 47: Rotavirus – Number of Infants Immunized (Million), 2011 - 2017
Figure 11 48: Rotavirus – Forecast for Number of Infants Immunized (Million), 2018 - 2024
Figure 11 35: Varicella – Total Number of Vaccinated People (Million), 2011 - 2017
Figure 11 36: Varicella – Forecast for Total Number of Vaccinated People (Million), 2018 - 2024
Figure 11 37: Varicella – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 11 38: Varicella – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 11 39: Varicella – Number of Vaccinated Infants (Million), 2011 - 2017
Figure 11 40: Varicella – Forecast for Number of Vaccinated Infants (Million), 2018 - 2024
Figure 12 1: Influenza – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 2: Influenza – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 3: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 4: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 5: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 6: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 7: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 8: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 9: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 10: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 11: MMR – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 12: MMR – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 13: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 14: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 15: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 16: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 17: Pneumococcal – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 18: Pneumococcal – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 19: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 20: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 21: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 22: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 23: Meningococcal – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 24: Meningococcal – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 25: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 26: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 27: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 28: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 29: Hepatitis – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 30: Hepatitis – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 12 31: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 32: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 33: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 34: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 35: TdaP and DTaP – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 36: TdaP and DTaP – Forecast for Doses of Vaccines Administered (million), 2018 - 2024
Figure 12 37: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 38: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 39: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 40: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 41: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 42: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 43: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 44: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 45: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 46: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 12 35: Varicella – Total Doses of Vaccines Administered (Million), 2011 - 2017
Figure 12 36: Varicella – Forecast for Total Doses of Vaccines Administered (million), 2018 - 2024
Figure 12 37: Varicella – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 12 38: Varicella – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 12 47: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2017
Figure 12 48: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2018 - 2024
Figure 14 1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14 2: Global – Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14 3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 14 4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 14 5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14 6: Global – Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14 7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 14 8: Global – Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 14 9: Global – Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 14 10: Global – Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 15 1: GSK Vaccine Product Pipeline
Figure 18 1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 18 2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 18 3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 18 4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 18 5: US Retail Clinics Expected to Surge by 2017

Lists of Tables
Table 2 1: Vaccine Recommendations
Table 2 2: Other Recommended Vaccines
Table 6 1: Global – Vaccinated People Share (Percent), 2011 - 2017
Table 6 2: Global – Forecast for Vaccinated People Share (Percent), 2018 – 2024
Table 13 1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 13 2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 13 3: Vaccines – Number of Reported Cases, 2011 – 2017
Table 13 4: Measles – Number of Reported Cases, 2001 – 2016
Table 13 5: Mumps – Number of Reported Cases, 2001 - 2016
Table 13 6: Rubella – Number of Reported Cases, 2001 - 2016
Table 13 7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
Table 13 8: Diphtheria – Number of Reported Cases, 2001 - 2016
Table 13 9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
Table 13 10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
Table 13 11: Pertussis – Number of Reported Cases, 2001 - 2016
Table 13 12: Polio – Number of Reported Cases, 2001 - 2016
Table 13 13: Yellow Fever – Number of Reported Cases, 2001 - 2016
Table 13 14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
Table 15 1: Merck Vaccine Product Pipeline
Table 15 2: Sanofi Vaccine Product Pipeline
Table 15 3: Pfizer Vaccine Product Pipeline
Table 16 1: Vaccine Mergers & Acquisitions
Table 18 1: United States Immunization Schedule
Table 18 2: Afghanistan Immunization Schedule
Table 18 3: Norway Immunization Schedule
Table 18 4: India Immunization Schedule
Table 18 5: Vietnam Immunization Schedule
Table 18 6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 18 7: Goal-Level Indicators, 2015 & 2020
Table 18 8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll